DesigneRx Pharmaceuticals (Chengdu) Inc. was founded in 2013 in Chengdu, China as a global protein drug production and R&D facility of Polaris Pharmaceuticals, Inc. The facility is located in the West Hi-Tech Zone of Chengdu, Sichuan province which is responsible for production and R&D of protein drugs and biologics. With Polaris Pharmceuticals’ R&D and technological advantages, DesigneRx (Chengdu) possesses essential techniques such as microbial culturing, protein purification, formulation, upstream & downstream processing of biologics, etc.
ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol) is a class one anti-cancer new drug that works on different metabolic needs between normal cells and cancer cells. ADI-PEG 20 depletes the extracellular key essential amino acid for cancer cells and thereby blocking its growth. ADI-PEG 20 is now in clinical Phase III trials with hepatocellular carcinoma in various countries around the world. Not only hepatocellular carcinoma, it has also been used for the clinical treatment of other types of arginine-dependent cancer such as interstitial lung cancer, leukemia, lymphoma, lung cancer, pancreatic cancer, melanoma, breast cancer, prostate cancer, etc. These clinical studies show that the effect is clear with mild side effects. ADI-PEG 20 also held global patent protection in many countries. U.S. FDA has approved ADI-PEG 20 as an orphan drug for the treatment of hepatocellular carcinoma, interstitial lung cancer and melanoma, and provided special testing scheme evaluation. EDQM has also approved the ADI-PEG 20 as an orphan drug for the treatment of hepatocellular carcinoma and interstitial lung cancer.
The facility of DesigneRx (Chengdu) is designed by world famous engineering/ design companies and domestic well-known design institute. To set up a world-first-class manufacturing process, we widely introduce state of the art manufacturing technologies from abroad as well as from domestic sources into our facility, and adapt it to our specific needs in drug production. The facility of DesigneRx (Chengdu) will meet the standards of U.S. FDA, EU cGMP and Chinese GMP, and the products will be distributed worldwide.